Anti-HIV-1 activity of anionic polymers: A comparative study of candidate microbicides

BMC Infectious Diseases

Volumn 2, Issue , 2002, Pages

  Neurath, A Robert ^a   Strick, Nathan ^a   Li, Yun Yao ^a  

^a NEW YORK BLOOD CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; CARBOPOL 974P; CARRAGEENAN; CELLACEFATE; CELLULOSE SULFATE; DEXTRAN SULFATE; GLYCOPROTEIN GP 120; NAPHTHALENESULFONIC ACID DERIVATIVE; POLYSTYRENESULFONIC ACID; ACRYLIC ACID RESIN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CELLULOSE; DEXTRAN; DRUG DERIVATIVE; GLYCOPROTEIN GP 41; SPERMICIDAL AGENT;

ANTIVIRAL ACTIVITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG MECHANISM; DRUG PROTEIN BINDING; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; NONHUMAN; POLYMERIZATION; REVIEW; VIRUS SHEDDING; ARTICLE; BLOOD CLOTTING; CELL CULTURE; CHEMISTRY; COMPARATIVE STUDY; DRUG EFFECT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MICROBIOLOGICAL EXAMINATION; PROTEIN SECONDARY STRUCTURE;

ACRYLIC RESINS; ANTI-HIV AGENTS; BLOOD COAGULATION; CARRAGEENAN; CELLS, CULTURED; CELLULOSE; DEXTRAN SULFATE; DEXTRANS; HIV ENVELOPE PROTEIN GP41; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; PROTEIN STRUCTURE, SECONDARY; SPERMATOCIDAL AGENTS;

EID: 0037153583     PISSN: 14712334     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-2334-2-27     Document Type: Review

References (63)

1. Baba M, Snoeck R, Pauwels R, De Clercq E: Sulfated polysaccharides are potent and selective inhibitors of various enveloped viruses, including herpes simplex virus, cytomegalovirus, vesicular stomatitis virus, and human immunodeficiency virus. Antimicrob Agents Chemother 1988, 32:1742-1745
2. Bagasra O, Lischner HW: Activity of dextran sulfate and other polyanionic polysaccharides against human immunodeficiency virus. J Infect Dis 1988, 158:1084-1087
3. Baba M, Schols D, Pauwels R, Nakashima H, De Clercq E: Sulfated polysaccharides as potent inhibitors of HIV-induced syncytium formation: A new strategy towards AIDS chemotherapy. J Acquir Immune Defic Syndr 1990, 3:493-499
4. McClure MO, Moore JP, Blanc DF, Scotting P, Cook GM, Keynes RJ, Weber JN, Davies D, Weiss RA: Investigations into the mechanism by which sulfated polysaccharides inhibit HIV infection in vitro. AIDS Res Hum Retroviruses 1992, 8:19-26
5. Lynch G, Low L, Li S, Sloane A, Adams S, Parish C, Kemp B, Cunningham AL: Sulfated polyanions prevent HIV infection of lymphocytes by disruption of the CD4-gp120 interaction, but do not inhibit monocyte infection. J Leukoc Biol 1994, 56:266-272
6. Shaunak S, Gooderham NJ, Edwards RJ, Payvandi N, Javan CM, Baggett N, MacDermot J, Weber JN, Davies DS: Infection by HIV-1 blocked by binding of dextrin 2-sulphate to the cell surface of activated human peripheral blood mononuclear cells and cultured T-cells. Br J Pharmacol 1994, 113:151-158
7. Davies DS: Dextrin sulfates as anti HIV-1 agents and composition thereof. US Patent 5,439,892
8. Javan CM, Gooderham NJ, Edwards RJ, Davies DS, Shaunak S: Anti- HIV type 1 activity of sulfated derivatives of dextrin against primary viral isolates of HIV type 1 in lymphocytes and monocyte-derived macrophages. AIDS Res Hum Retroviruses 1997, 13:875-880
9. Stafford MK, Cain D, Rosenstein I, Fontaine EA, McClure M, Flanagan AM, Smith JR, Taylor-Robinson D, Weber J, Kitchen VS: A placebocontrolled, double-blind prospective study in healthy female volunteers of dextrin sulphate gel: A novel potential intravaginal virucide. J Acquir Immune Defic Syndr Hum Retrovirol 1997, 14:213-218
10. Baba M, Pauwels R, Balzarini J, Arnout J, Desmyter J, De Clercq E: Mechanism of inhibitory effect of dextran sulfate and heparin on replication of human immunodeficiency virus in vitro . Proc Natl Acad Sci U S A 1988, 85:6132-6136
11. Rosenstein IJ, Stafford MK, Kitchen VS, Ward H, Weber JN, Taylor-Robinson D: Effect on normal vaginal flora of three intravaginal microbicidal agents potentially active against human immunodeficiency virus type 1. J Infect Dis 1998, 177:1386-1390
12. Yamamoto I, Takayama K, Honma K, Gonda T, Matsuzaki K, Hatanaka K, Uryu T, Yoshida O, Nakashima H, Yamamoto N, et al: Synthesis, structure and antiviral activity of sulfates of cellulose and its branched derivatives. Carbohydrate Polymers 1991, 14:53-63
13. Anderson RA, Zaneveld LJD, Usher TC: Cellulose sulfate for use as antimicrobial and contraceptive agent. US Patent 6,063,773
14. Mauck C, Frezieres R, Walsh T, Robergeau K, Callahan M: Cellulose sulfate: tolerance and acceptability of penile application. Contraception 2001, 64:377-381
15. Mauck C, Weiner DH, Ballagh S, Creinin M, Archer DF, Schwartz J, Pymar H, Lai JJ, Callahan M: Single and multiple exposure tolerance study of cellulose sulfate gel: a Phase I safety and colposcopy study. Contraception 2001, 64:383-391
16. Carlucci MJ, Pujol CA, Ciancia M, Noseda MD, Matulewicz MC, Damonte EB, Cerezo AS: Antiherpetic and anticoagulant properties of carrageenans from the red seaweed Gigartina skottsbergii and their cyclized derivatives: correlation between structure and biological activity. Int J Biol Macromol 1997, 20:97-105
17. Coggins C, Blanchard K, Alvarez F, Brache V, Weisberg E, Kilmarx PH, Lacarra M, Massai R, Mishell D Jr, Salvatierra A, et al: Preliminary safety and acceptability of a carrageenan gel for possible use as a vaginal microbicide. Sex Transm Infect 2000, 76:480-483
18. Schaeffer DJ, Krylov VS: Anti-HIV activity of extracts and compounds from algae and cyanobacteria. Ecotoxicol Environ Saf 2000, 45:208-227
19. Maguire RA, Bergman N, Phillips DM: Comparison of microbicides for efficacy in protecting mice against vaginal challenge with herpes simplex virus type 2, cytotoxicity, antibacterial properties, and sperm immobilization. Sex Transm Dis 2001,28:259-265
20. Anderson RA, Feathergill K, Diao X, Cooper M, Kirkpatrick R, Spear P, Waller DP, Chany C, Doncel GF, Herold B, et al: Evaluation of poly(styrene-4-sulfonate) as a preventive agent for conception and sexually transmitted diseases. J Androl 2000, 21:862-875
21. Christensen ND, Reed CA, Culp TD, Hermonat PL, Howett MK, Anderson RA, Zaneveld LJ: Papillomavirus microbicidal activities of high-molecular-weight cellulose sulfate, dextran sulfate, and polystyrene sulfonate. Antimicrob Agents Chemother 2001, 45:3427-3432
22. Rusconi S, Moonis M, Merrill DP, Pallai PV, Neidhardt EA, Singh SK, Willis KJ, Osburne MS, Profy AT, Jenson JC, et al: Naphthalene sulfonate polymers with CD4-blocking and anti-human immunodeficiency virus type 1 activities. Antimicrob Agents Chemother 1996, 40:234-236
23. Van Damme L, Wright A, Depraetere K, Rosenstein I, Vandersmissen V, Poulter L, McKinlay M, Van Dyck E, Weber J, Profy A, et al: A phase I study of a novel potential intravaginal microbicide, PRO2000 in healthy sexually inactive women. Sex Transm Dis 2000, 76:126-130
24. 89.6PD in vitro and in vivo. AIDS 2001, 15:1563-1568
25. Olmsted SS, Dubin NH, Cone RA, Moench TR: The rate at which human sperm are immobilized and killed by mild acidity. Fertil Steril 2000, 73:687-693
26. Clarke JG, Peipert JF, Hillier SL, Heber W, Boardman L, Moench TR, Mayer K: Microflora changes with the use of a vaginal microbicide. Sex Transm Dis 2002, 29:288-293
27. Zeitlin L, Hoen TE, Achilles SL, Hegarty TA, Jerse AE, Kreider JW, Olmsted SS, Whaley KJ, Cone RA, Moench TR: Tests of BufferGel for contraception and prevention of sexually transmitted diseases in animal models. Sex Transm Dis 2001, 28:417-423
28. Mayer KH, Peipert J, Fleming T, Fullem A, Moench T, Cu-Uvin S, Bentley M, Chesney M, Rosenberg Z: Safety and tolerability of BufferGel, a novel vaginal microbicide, in women in the United States. Clin Infect Dis 2001, 32:476-482
29. van de Wijgert J, Fullem A, Kelly C, Mehendale S, Rugpao S, Kumwenda N, Chirenje Z, Joshi S, Taha T, Padian N, et al: Phase 1 trial of the topical microbicide BuffferGel: Safety results from four international sites. J Acquir Immune Defic Syndr 2001, 26:21-27
30. Gyotoku T, Aurelian L, Neurath AR: Cellulose acetate phthalate (CAP): an 'inactive' pharmaceutical excipient with antiviral activity in the mouse model of genital herpesvirus infection. Antivir Chem Chemother 1999, 10:327-332
31. Neurath AR, Strick N, Li Y-Y, Lin K, Jiang S: Design of a "microbicide" for prevention of sexually transmitted diseases using "inactive" pharmaceutical excipients. Biologicals 1999, 27:11-21
32. Neurath AR, Li YY, Mandeville R, Richard L: In vitro activity of a cellulose acetate phthalate topical cream against organisms associated with bacterial vaginosis. J Antimicrob Chemother 2000, 45:713-714
33. Neurath AR: A microbicide for prevention of sexually transmitted diseases using a pharmaceutical excipient. AIDS Patient Care STDS 2000, 14:215-219
34. Manson KH, Wyand MS, Miller C, Neurath AR: The effect of a cellulose acetate phthalate topical cream on vaginal transmission of simian immunodeficiency virus in rhesus monkeys. Antimicrob Agents Chemother 2000, 44:3199-3202
35. Kawamura T, Cohen SS, Borris DL, Aquilino EA, Glushakova S, Margolis LB, Orenstein JM, Offord RE, Neurath AR, Blauvelt A: Candidate microbicides block HIV-1 infection of human immature Langerhans cells within epithelial tissue explants. J Exp Med 2000, 192:1491-1500
36. Neurath AR, Strick N, Li YY, Debnath AK: Cellulose acetate phthalate, a common pharmaceutical excipient, inactivates HIV-1 and blocks the coreceptor binding site on the virus envelope glycoprotein gp120. BMC Infect Dis 2001, 1:17
37. Neurath AR, Strick N, Jiang S, Li YY, Debnath AK: Anti-HIV-1 activity of cellulose acetate phthalate: Synergy with soluble CD4 and induction of "dead-end" gp41 six-helix bundles. BMC Infect Dis 2002, 2:6
38. Greenhead P, Hayes P, Watts PS, Laing KG, Griffin GE, Shattock RJ: Parameters of human immunodeficiency virus infection of human cervical tissue and inhibition by vaginal virucides. J Virol 2000, 74:5577-5586
39. Shattock RJ, Doms RW: AIDS models: Microbicides could learn from vaccines. Nat Med 2002, 8:425
40. O'Connor TJ, Kinchington D, Kangro HO, Jeffries DJ: The activity of candidate virucidal agents, low pH and genital secretions against HIV-1 in vitro. Int J STD AIDS 1995, 6:267-272
41. Berger EA, Doms RW, Fenyo EM, Korber BT, Littman DR, Moore JP, Sattentau QJ, Schuitemaker H, Sodroski J, Weiss RA: A new classification for HIV-1. Nature 1998, 391:240
42. Larsen B: Vaginal flora in health and disease. Clin Obstet Gynecol 1993, 36:107-121
43. Jiang S, Lin K, Lu M: A conformation-specific monoclonal antibody reacting with fusion-active gp41 from the human immunodeficiency virus type 1 envelope glycoprotein. J Virol 1998, 72:10213-10217
44. Neurath AR, Strick N, Li Y-Y, Jiang S: Improbability of harmful autoimmune responses resulting from immunization with HIV-1 envelope glycoproteins. AIDS Res Hum Retroviruses 1993, 9:1195-1208
45. Jiang S, Lin K, Zhang L, Debnath AK: A screening assay for antiviral compounds targeted to the HIV-1 gp41 core structure using a conformation-specific monoclonal antibod J Virol Methods 1999, 80:85-96
46. Gartner S, Markovits P, Markovitz DM, Kaplan MH, Gallo RC, Popovic M: The role of mononuclear phagocytes in HTLV-III/LAV infection. Science 1986, 233:215-219
47. Stoll VS, Blanchard JS: Buffers: Principles and Practice In Methods in Enzymology, Guide to Protein Purification (Edited by: Deutscher MP) San Diego, CA., Academic Press, Inc 1990, 182:24-38
48. Huang L, Bosch I, Hofmann W, Sodroski J, Pardee AB: Tat protein induces human immunodeficiency virus type 1 (HIV-1) coreceptors and promotes infection with both macrophage-tropic and T-lymphotropic HIV-1 strains. J. Virol 1998, 72:8952-8960
49. Secchiero P, Zella D, Capitani S, Gallo RC, Zauli G: Extracellular HIV-1 tat protein up-regulates the expression of surface CXC-chemokine receptor 4 in resting CD4+ T cells. J Immunol 1999, 162:2427-2431
50. Rasheed S, Li Z, Xu D: Human immunodeficiency virus load. Quantitative assessment in semen from seropositive individuals and in spiked seminal plasma. J Reprod Med 1995, 40:747-757
51. Krieger JN, Coombs RW, Collier AC, Ho DD, Ross SO, Zeh JE, Corey L: Intermittent shedding of human immunodeficiency virus in semen: implications for sexual transmission. J Urol 1995, 154:1035-1040
52. Allen RD, Roberts TK: Role of spermine in the cytotoxic effects of seminal plasma. Am J Reprod Immunol Microbiol 1987, 13:4-8
53. Masters W, Johnson V: Sexual physiology and AIDS protection. In AIDS and Sex (Edited by: Voeller B, Reinisch J, Gottlieb M) New York, Oxford University Press 1990, 371-374
54. Goskonda SR, Lee JC: Cellulose Acetate Phthalate. In Handbook of Pharmaceutical Excipients (Edited by: Kibbe AH, Washington, DC) American Pharmaceutical Association 2000, 99-101
55. de Raucourt E, Mauray S, Chaubet F, Maiga-Revel O, Jozefowicz M, Fischer AM: Anticoagulant activity of dextran derivatives. J Biomed Mater Res 1998, 41:49-57
56. Izumi T, Hirata M: Complexation of papain with strong polyanions and enzymatic activities of the resulting complexes. J Macromol Sci, Pure Appl Chem 1994, A31(1):39-51
57. Sedlak E, Antalik M: Coulombic and noncoulombic effect of polyanions on cytochrome c structure. Biopolymers 1998, 46:145-154
58. Dyer JR, Kazembe P, Vernazza PL, Gilliam BL, Maida M, Zimba D, Hoffman IF, Royce RA, Schock JL, Fiscus SA, et al: High levels of human immunodeficiency virus type 1 in blood and semen of seropositive men in sub-Saharan Africa. J Infect Dis 1998, 177:1742-1746
59. Chakraborty H, Sen PK, Helms RW, Vernazza PL, Fiscus SA, Eron JJ, Patterson BK, Coombs RW, Krieger JN, Cohen MS: Viral burden in genital secretions determines male-to-female sexual transmission of HIV-1: a probabilistic empiric model. AIDS 2001, 15:621-627
60. Kadla JF, Gilbert RD: Cellulose structure: A review. Cellulose Chemistry and Technology 2000, 34:197-216
61. Cheetham NWH, Fiala-Beer E: Dextran structural details from high-field proton NMR spectroscopy. Carbohydrate Polymers 1991, 14:149-158
62. Reilly WJ Jr: Carrageenan. In Handbook of Pharmaceutical Excipients (Edited by: Kibbe AH, Washington, DC) American Pharmaceutical Association 2000, 91-93
63. Caram-Lelham N, Sundelof LO: The effect of hydrophobic character of drugs and helix-coil transition of κ-carrageenan on the polyelectrolyte-drug interaction. Pharm Res 1996, 13:920-925